There are no products listed under this category.
HSD17B11
HSD17B11 (hydroxysteroid 17-beta dehydrogenase 11, also known as RetSDR2, 17-BETA-HSD11, PAN1B, SDR16C2 and DHRS8) is a short-chain dehydrogenase/reductase that converts 3-alpha-diol to androsterone in vitro. It is linked to androgen metabolism during steroidogenesis. Browse Assay Genie's current range of HSD17B11 research reagents below, or read on for the biology behind the target.
HSD17B11 is an oxidoreductase of the short-chain dehydrogenase/reductase (SDR) superfamily. Short-chain alcohol dehydrogenases of this kind metabolise secondary alcohols and ketones. In vitro, HSD17B11 can convert androstan-3-alpha,17-beta-diol (3-alpha-diol) to androsterone, which suggests a role in androgen metabolism during steroidogenesis. It may act by metabolising compounds that stimulate steroid synthesis, by generating metabolites that inhibit it, or both.
The enzyme is selective. It has no activity toward DHEA (dehydroepiandrosterone) or A-dione (4-androste-3,17-dione), and only slight activity in converting testosterone to A-dione. The protein localises to the endoplasmic reticulum and to lipid droplets. It belongs to the 17-beta-HSD 3 subfamily of the SDR family, and the HSD17B11 gene is conserved in mouse and rat, where the orthologue is named Hsd17b11. Researchers studying the HSD17B11 protein often use it as a model for how SDR enzymes handle steroid substrates.
The gene has been catalogued under several names. Earlier HGNC names include dehydrogenase/reductase (SDR family) member 8 and hydroxysteroid (17-beta) dehydrogenase 11, and aliases include RetSDR2, 17-BETA-HSD11, 17-BETA-HSDXI, PAN1B, SDR16C2 and DHRS8. UniProt also describes HSD17B11 as a tumour-associated antigen in cutaneous T-cell lymphoma, which links this metabolic enzyme to cancer immunology research.
HSD17B11 converts 3-alpha-diol to androsterone in vitro, making it a candidate participant in androgen metabolism during steroidogenesis.
It may metabolise compounds that stimulate steroid synthesis or generate metabolites that inhibit it, so it is studied as a modulator of steroid output.
HSD17B11 is described as a tumour-associated antigen in cutaneous T-cell lymphoma, supporting its use in tumour antigen research.
As a member of the short-chain dehydrogenase/reductase superfamily, it helps researchers examine how these enzymes metabolise secondary alcohols and ketones.
HSD17B11 is a short-chain dehydrogenase/reductase that converts androstan-3-alpha,17-beta-diol to androsterone in vitro. This suggests a role in androgen metabolism during steroidogenesis. It has no activity toward DHEA or A-dione and only slight activity toward testosterone.
HSD17B11 is also called RetSDR2, 17-BETA-HSD11, 17-BETA-HSDXI, PAN1B, SDR16C2 and DHRS8. UniProt names it estradiol 17-beta-dehydrogenase 11. Earlier HGNC names were dehydrogenase/reductase (SDR family) member 8 and hydroxysteroid (17-beta) dehydrogenase 11.
Mouse and rat both have an orthologue named Hsd17b11. UniProt describes human HSD17B11 as a tumour-associated antigen in cutaneous T-cell lymphoma. Check the datasheet of any product for its validated reactivity.
Other hydroxysteroid dehydrogenases and steroid-metabolism enzymes with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q8NBQ5; product specifications from Assay Genie datasheets.
There are no products listed under this category.